Brief: Aim Immunotech Broadens Patent Portfolio With New Netherlands Utility Patent Covering Ampligen® And Other Aim-Developed Dsrna Products To Include Rugged Dsrna For Use In Covid-19 Treatment Or Prevention
09/01/2023 13:36
Jan 9 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH BROADENS PATENT PORTFOLIO WITH NEW
NETHERLANDS
UTILITY PATENT COVERING AMPLIGEN® AND OTHER AIM-DEVELOPED DSRNA
PRODUCTS TO INCLUDE RUGGED DSRNA FOR USE IN COVID-19 TREATMENT
OR PREVENTION
Source text for Eikon: ID:nGNX4pPHHt
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential